In past the polymorphism of CYP2C9 and CYP2C19 genes in the patients with pulmonary tuberculosis (TB) have been studied. The aim of present research was an investigation of combined polymorphism of СYP2C9 and СYP2C19 genes in TB-patients and its influence on rifampicin level in blood.
A genotype of CYP450 2C19 and 2С9 was detected with the help of polymerase chain reaction (PCR) according to J. A. Goldstein, J. Blaisdell, 2004 and T. H. Sullivan-Klose et al., correspondently. The level of rifampicin has been measured according to V. T. Chubaryan 2, 4, 6 and 24 hours after ingestion.
Among TB-patients the individuals with following CYP2C9 and 2C19 genotype (“rapid metabolizers” + “moderate metabolizers”; “slow metabolizers”) were 2 times more common, than in control group (54.8% versus 27.9%; p=0,003; c2=8,687). The highest serum rifampicin level 24 hours after ingestion as well as the lowest number of sub-effective rifampicin level in blood has been observed in the individuals with following CYP2C9 and 2C19 genotype (“slow metabolizers”+“rapid metabolizers”). In the next papers we are going to study an influence of combined CYP2C9 and 2С19 genes polymorphism on effectiveness and safety of anti-tuberculosis therapy.